Thursday, May 19th 2022 (11:00 - 12:30)


€0 for non-members

€0 for members



Organised by

Janssen Pharmaceutica



Has your life sciences or medtech startup identified their long-term exit strategy, including strategic endgame and plan for getting there? Johnson & Johnson Innovation will provide a no-nonsense guide to key aspects of exits as the market-leading technology team from Allen & Overy shares deep insights in M&A from different global ecosystems.

Join us in Leiden, the Netherlands, or virtually:

What will you answer when a potential investor asks you how and when they’ll get a return on their investment?


Whatever your company’s ambitions are in terms of Initial Public Offering (IPO), Mergers & Acquisitions (M&A) or licensure, you will probably want to keep your options open in the early stages of your company’s development. Have you identified your long-term exit strategy, including your strategic endgame and a plan for getting there?


During this interactive session Johnson & Johnson Innovation aims to provide a no-nonsense guide to key aspects of exits through M&A, focused on early-stage life sciences and medtech companies with deep IP.


The program will be led by experts from Allen & Overy’s market-leading technology team who have deep experience in Mergers & Acquisitions (M&A) in different global ecosystems including Silicon Valley. They will share insights into:


- what to expect from acquirers and investors;

- how to create a strong position for negotiations;

- approaches you might expect from buyers;

- differences between the USA, UK and EU;

- common pitfalls and how to avoid them.


Following the workshop, Allen & Overy will provide one-to-one mentoring sessions (25 minutes each) for selected companies. Please see below for more information including application details.

Join us in Leiden, the Netherlands, or virtually: